Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ALTA3263 + cetuximab
- Development stage
- Phase 1
- Lead developer
- Alterome Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
ALTA3263 + cetuximab is an investigational combination regimen consisting of ALTA3263, an orally bioavailable, KRAS-selective, pan-mutant (ON/OFF) inhibitor, and cetuximab, an approved anti-EGFR monoclonal antibody. Developed by Alterome Therapeutics, the combination is designed to target KRAS-mutant solid tumors. ALTA3263 potently inhibits a broad range of oncogenic KRAS mutations in both active (ON) and inactive (OFF) states while sparing wild-type HRAS and NRAS. Cetuximab blocks EGFR signaling, which preclinically has shown synergistic antitumor activity when combined with KRAS inhibition in colorectal and pancreatic cancer models. The combination is being evaluated in a Phase 1/1b clinical trial (NCT06835569) for patients with advanced solid tumors harboring KRAS mutations, with an initial focus on colorectal cancer (CRC) and pancreatic ductal adenocarcinoma (PDAC).
- Other names
- ALTA-3263 + cetuximabALTA-3263 + ErbituxALTA3263 + Erbitux
02
Targets
Beyond the preview
Go deeper on ALTA3263 + cetuximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ALTA3263 + cetuximab.